Tatiana Valderrama, APN-C

Tatiana Valderrama practices at The Gastroenterology Group of Northern New Jersey in Englewood Cliffs, New Jersey.

Tatiana Valderrama's NPI, 1831423052, was assigned on September 21, 2009. Tatiana Valderrama holds New Jersey license 26NJ00206200.

Tatiana Valderrama's primary practice is The Gastroenterology Group of Northern New Jersey, at 140 Sylvan Ave, Englewood Cliffs, NJ 07632 in Bergen County. The practice phone is (201) 945-6564.

Tatiana Valderrama's primary practice is The Gastroenterology Group of Northern New Jersey in Englewood Cliffs, New Jersey. Tatiana Valderrama is also affiliated with Englewood Hospital. The medical group on file is Allied Digestive Health. Dmand AI also links Tatiana Valderrama to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Tatiana Valderrama practices, 2 sites in all. Vendor and product names are available with a free account.

Nurse practitioner is Tatiana Valderrama's primary specialty in the NPI Registry, under taxonomy code 363L00000X. Tatiana Valderrama is licensed in New Jersey.

CMS counts 276 Medicare patients who saw Tatiana Valderrama in 2024. The largest group is 75 to 84, with 114 patients. 75% of them have high cholesterol, and 67% have high blood pressure. 7% are also on Medicaid. Their average risk score is 1.16, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Tatiana Valderrama's median patient age at 67, with 65% women.

In 2024, Tatiana Valderrama wrote 430 Medicare Part D claims for 183 patients. 87% of them were for generic drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 98 out of 100 for Tatiana Valderrama for performance year 2024, reported as part of a group. Tatiana Valderrama accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Tatiana Valderrama as offering telehealth.

CMS Open Payments shows 31 general payments to Tatiana Valderrama from 12 drug and device companies in 2025. Food and beverage make up the largest share, 85% of the total. Abbvie Inc. paid the most, $144.